Celator Pharmaceuticals(R) Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS(TM) (CPX-351) Significantly Improved Overall Survival

June 6, 2016

First therapy to demonstrate statistically significant improvement in overall survival and induction response rate in a pivotal Phase 3 trial in high-risk AML
More »

JAZZ PHARMACEUTICALS AND CELATOR PHARMACEUTICALS ANNOUNCE AGREEMENT FOR JAZZ PHARMACEUTICALS TO ACQUIRE CELATOR FOR $30.25 PER SHARE

May 31, 2016

Transaction would add VYXEOS™, an investigational product in development as a treatment for Acute Myeloid Leukemia (AML), to Jazz Pharmaceuticals’ portfolio
More »

Celator Pharmaceuticals® Announces VYXEOS™ Granted Breakthrough Therapy Designation

May 19, 2016

FDA awards designation for treatment of adults with therapy-related AML or AML with myelodysplasia-related changes.
More »